Plaque Psoriasis Market – IL-23 Inhibitors Demonstrating...

agregó una foto Health

2026-09-21 07:06:46 -

Plaque Psoriasis Market – IL-23 Inhibitors Demonstrating Durable Skin Clearance with Quarterly Dosing

Market OverviewIL-23 inhibitors are demonstrating durable skin clearance with convenient quarterly dosing for plaque psoriasis patients, establishing themselves as preferred biologic class for many individuals seeking sustained efficacy with minimal treatment burden. Guselkumab, risankizumab, and tildrakizumab are achieving PASI 90 and PASI 100 response rates exceeding 80 percent in clinical...

0 Commentarios 0 Acciones 20 Views 0 Vista previa